|
WO2021003348A1
|
|
Hiv antigens and mhc complexes
|
|
WO2020243719A1
|
|
Modified adenoviruses
|
|
TW202100168A
|
|
Identification of neoantigens with mhc class ii model
|
|
WO2020180648A1
|
|
Selection of t cell receptors
|
|
WO2020160189A1
|
|
Multispecific binding proteins
|
|
WO2020097393A1
|
|
Alphavirus neoantigen vectors and interferon inhibitors
|
|
WO2020037302A1
|
|
Antigen-binding proteins targeting shared antigens
|
|
WO2019226941A1
|
|
Shared antigens
|
|
EP3796930A1
|
|
Immune checkpoint inhibitor co-expression vectors
|
|
AU2019227813A1
|
|
Neoantigen identification with pan-allele models
|
|
EP3731876A1
|
|
Antigen-binding proteins targeting shared antigens
|
|
WO2019104203A1
|
|
Reducing junction epitope presentation for neoantigens
|
|
AU2018348165A1
|
|
Neoantigen identification using hotspots
|
|
WO2019050994A1
|
|
Neoantigen identification for t-cell therapy
|
|
CN111328288A
|
|
Antigen binding proteins targeting common antigens
|
|
KR20200016265A
|
|
Identification, manufacture, and uses of new antigens
|
|
CA3062591A1
|
|
Alphavirus neoantigen vectors
|
|
MX2019012433A
|
|
Neoantigen identification, manufacture, and use.
|
|
MX2019006010A
|
|
Viral delivery of neoantigens.
|
|
KR20180107102A
|
|
Identification of new antigens, manufacture, and uses
|
